Fiche publication
Date publication
juin 2017
Journal
Journal of translational medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BETTAIEB Ali
,
Pr GHIRINGHELLI François
,
Pr PAUL Catherine
Tous les auteurs :
Bettaieb A, Paul C, Plenchette S, Shan J, Chouchane L, Ghiringhelli F
Lien Pubmed
Résumé
Many cancers, including breast cancer, have demonstrated prognosis and support advantages thanks to the discovery of targeted therapies. The advent of these new approaches marked the rise of precision medicine, which leads to improve the diagnosis, prognosis and treatment of cancer. Precision medicine takes into account the molecular and biological specificities of the patient and their tumors that will influence the treatment determined by physicians. This new era of medicine is accessible through molecular genetics platforms, the development of high-speed sequencers and means of analysis of these data. Despite the spectacular results in the treatment of cancers including breast cancer, described in this review, not all patients however can benefit from this new strategy. This seems to be related to the many genetic mutations, which may be different from one patient to another or within the same patient. It comes to give new impetus to the research-both from a technological and biological point of view-to make the hope of precision medicine accessible to all.
Mots clés
Breast cancer, Chemotherapy, HER2+, Immunotherapy, Molecular subtypes, Phase III clinical trials, Precision medicine, Triple-negative, Tumor heterogeneity
Référence
J Transl Med. 2017 Jun;15(1):139
